| Bid | 32.1 |
| Market Cap | 253.49M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.45 |
| PE Ratio (ttm) | -80.6 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 42.7 |
| Volume | 85,735 |
| Avg. Volume (20D) | 2,824,434 |
| Open | 35.41 |
| Previous Close | 35.41 |
| Day's Range | 35.02 - 36.51 |
| 52-Week Range | 0.93 - 79.02 |
| Beta | undefined |
About DRUG
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Bra...
Analyst Forecast
According to 3 analyst ratings, the average rating for DRUG stock is "Buy." The 12-month stock price forecast is $80, which is an increase of 120.57% from the latest price.
3 months ago · proactiveinvestors.co.uk
Canadian psychedelics company Bright Minds shares rise 1,446% in one dayYesterday, Bright Minds Biosciences Inc (CSE:DRUG, OTCQB:BMBIF), a biotech in the field of psychedelics, saw its shares rocket by a frankly psychedelic-looking 1,445.8% to $38.49 from $2.50 at the sta...
